Linked Life Data

19282460

Source:http://linkedlifedata.com/resource/pubmed/id/19282460

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
26
pubmed:dateCreated
2009-6-26
pubmed:abstractText
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a potent adjuvant in cancer vaccination; however, the specific role of endogenous GM-CSF remains unknown. We performed cell-based vaccination in 2 tumor models. First, we vaccinated C57BL/6 mice lacking either GM-CSF, IL-5, or beta-common chain (betac), a receptor subunit essential for GM-CSF and IL-5 signaling, with melanoma cells engineered to produce GM-CSF. Tumor vaccination was effective in both GM-CSF(-/-) and IL-5(-/-) mice, showing that protective immunization is independent of both endogenous cytokines. However, all betac(-/-) animals developed tumor. Loss of tumor immunity in betac(-/-) mice does not reflect global impairment in cell-mediated immunity, as contact hypersensitivity reaction to haptens is unaltered. The importance of tumor cell-derived GM-CSF was highlighted by recruitment of dendritic cells at the vaccination site in wild-type, GM-CSF(-/-), and IL-5(-/-) but not in betac(-/-) mice. In the second model, vaccination with unmodified RENCA cells showed similar results with efficient immunization in BALB/c wild-type and GM-CSF(-/-), whereas all betac(-/-) animals died. Altogether, our results strongly suggest that although endogenous GM-CSF and IL-5 are not required to induce tumor immunity, signaling through betac receptor is critically needed for efficient cancer vaccination in both genetically modified GM-CSF-secreting tumor cells and a spontaneously immunogenic models.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
25
pubmed:volume
113
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6658-68
pubmed:dateRevised
2010-10-6
pubmed:meshHeading
pubmed-meshheading:19282460-Animals, pubmed-meshheading:19282460-Cancer Vaccines, pubmed-meshheading:19282460-Carcinoma, Renal Cell, pubmed-meshheading:19282460-Cell Line, Tumor, pubmed-meshheading:19282460-Culture Media, Conditioned, pubmed-meshheading:19282460-Cytokine Receptor Common beta Subunit, pubmed-meshheading:19282460-Cytokines, pubmed-meshheading:19282460-Dendritic Cells, pubmed-meshheading:19282460-Dermatitis, Contact, pubmed-meshheading:19282460-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:19282460-Injections, Subcutaneous, pubmed-meshheading:19282460-Interleukin-3, pubmed-meshheading:19282460-Interleukin-5, pubmed-meshheading:19282460-Kidney Neoplasms, pubmed-meshheading:19282460-Melanoma, Experimental, pubmed-meshheading:19282460-Mice, pubmed-meshheading:19282460-Mice, Inbred BALB C, pubmed-meshheading:19282460-Mice, Inbred C57BL, pubmed-meshheading:19282460-Mice, Knockout, pubmed-meshheading:19282460-Recombinant Fusion Proteins, pubmed-meshheading:19282460-Species Specificity, pubmed-meshheading:19282460-Vaccination
pubmed:year
2009
pubmed:articleTitle
Role of GM-CSF signaling in cell-based tumor immunization.
pubmed:affiliation
Oncology Division, Department of Internal Medicine, Geneva University Hospital and Geneva Medical School, 24 Rue Micheli-du-Crest, Geneva, Switzerland.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural